Advaxis

Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. Its lead candidates are the oral gamma secretase inhibitor, AL102, for desmoid tumors, and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. The company was founded on June 5, 1987 and is headquartered in Monmouth Junction, NJ.

Kaixin Auto Holdings

Senseonics Holdings

Are these penny stocks on your September small-caps watchlist? The post Trending Penny Stocks to Buy in September?

Trending Penny Stocks to Buy in September? Check These 3 Out

MONMOUTH JUNCTION, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (“Advaxis” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products, announced that it has received a letter indicating that following the Company's hearing before the Nasdaq Hearings Panel (the “Panel”), the Panel determined to grant the Company an extension through November 22, 2021, to comply with Nasdaq's $1.00 Minimum Bid Price Rule and complete its previously announced merger transaction with Biosight, Ltd. (“Biosight”). On July 6, 2021, Advaxis announced that it had entered into a merger agreement with Biosight, a privately held, Israel-based pharmaceutical company developing innovative therapeutics for hematological malignancies and disorders.

Nasdaq Grants Advaxis, Inc. an Extension to November 22, 2021, to Regain Compliance with the $1.00 Minimum Bid Price Rule and Complete Merger Transaction with Biosight, Ltd.

Vinco Ventures

Cemtrex

Tellurian

Why These 3 Penny Stocks Are Popular Among Traders Right Now The post Popular Penny Stocks to Buy in 2021? Here's 4 You Should Know About appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Popular Penny Stocks to Buy in 2021? Here's 4 You Should Know About

Ambev

Ashford Hospitality Trust

Aerpio Pharmaceuticals Inc

Globalstar

Sonim Technologies Inc

Reopening penny stocks are showing momentum right now; here's 6 to watch The post Hot Penny Stocks to Buy Now? 6 Reopening Stocks To Watch In July 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks to Buy Now? 6 Reopening Stocks To Watch In July 2021

NEW YORK, July 16, 2021 /PRNewswire/-- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Advaxis, Inc. ("ADXS" or the "Company") (ADXS) relating to its proposed merger with BioSight Ltd. The investigation focuses on whether Advaxis, Inc. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, and 2) whether the transaction is properly valued.

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Advaxis, Inc. - ADXS

Advaxis Inc (NASDAQ: ADXS) has initiated a Phase 1 study evaluating ADXS-504 in patients with recurrent prostate cancer.  The study, being conducted at Columbia University Irving Medical Center, is the first clinical evaluation of ADXS-504, Advaxis' off-the-shelf neoantigen immunotherapy drug candidate for early prostate cancer.

Advaxis Kick Starts Early-Stage Study For Prostate Cancer Immunotherapy

Study in biochemically recurrent prostate cancer expands off-the-shelf ADXS-HOT program to second indication Study in biochemically recurrent prostate cancer expands off-the-shelf ADXS-HOT program to second indication

Advaxis Announces Initiation of Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer

PRINCETON, N.J., July 14, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Andres Gutierrez, M.D., Executive Vice President and Chief Medical Officer of Advaxis, will present data from Part B of the Company's Phase 1/2 study of ADXS-503 in combination with Pembrolizumab in patients with metastatic squamous or non-squamous non-small cell lung cancer at the virtual Non-Small Cell Lung Cancer Drug Development Summit on July 15th, 2021.

Advaxis to Present at the Non-Small Cell Lung Cancer Drug Development Summit

Broadway Financial

Cinedigm

DarkPulse, Inc.

Sphere 3D

ZW Data Action Technologies Inc.

Ebang International Holdings

Are you familiar with these hot penny stocks to watch? 7 to keep an eye on right now The post 7 Top Penny Stocks to Watch That You Probably Haven't Heard Of appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

7 Top Penny Stocks to Watch That You Probably Haven't Heard Of

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Advaxis, Inc. (NasdaqGS: ADXS) (“the Company”) with Biosight Ltd. pursuant to which Advaxis shareholders will own approximately 25% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company. If you believ

ADVAXIS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Advaxis, Inc. - ADXS

NEW YORK, July 6, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Advaxis, Inc. ("Advaxis" or the "Company") (NASDAQ: ADXS) in connection with the proposed merger of the Company with privately-held pharmaceutical development company, Biosight Ltd. ("Biosight").

SHAREHOLDER ALERT: WeissLaw LLP Investigates Advaxis, Inc.

Second Sight Medical Products

Rigel Pharmaceuticals

SenesTech

Biotech penny stocks continue to climb, which companies are on your watchlist? The post Top Biotech Penny Stocks to Buy This Week?

Top Biotech Penny Stocks to Buy This Week? 9 To Watch

The stock price of Advaxis, Inc. (NASDAQ: ADXS) increased by over 30% during intraday trading. This is why it happened.

ADXS Stock Increases Over 30%: Why It Happened

ALX Onconology Holdings Inc

Odonate Therapeutics

Provention Bio Inc

Odonate Therapeutics, Inc. (NASDAQ: ODT), Opthea Limited (NASDAQ: OPT), ALX Oncology Holdings Inc. (NASDAQ: ALXO), Provention Bio, Inc. (NASDAQ: PRVB) and Advaxis, Inc. (NASDAQ: ADXS) are among the biggest biopharma movers Tuesday. Odonate Gains On Institutional Stake: Shares of Odonate, a biopharma which recently announced discontinuation of development of an oral chemotherapy candidate named tesetaxel, are seeing renewed buying following disclosure of institutional stake.

Why Odonate Therapeutics, Opthea, ALX Oncology, Advaxis and Provention Bio Are Moving Today

– Combined Company Will Operate as Biosight Therapeutics to Advance Pipeline of Clinical-Stage Oncology Programs with Lead Program Aspacytarabine (BST-236) in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Advaxis and Biosight Announce Entry into Definitive Merger Agreement

ADXS-503 Phase 1/2 trial data presented at ASCO demonstrate disease control rate of 44% with durable clinical benefit observed beyond one year in patients with disease progression on KEYTRUDA®

Advaxis Reports Second Quarter Ended April 30, 2021 Financial Results and Provides a Business Update

Sesen Bio Inc.

T2 Biosystems

Tyme Technologies

Biotech penny stocks are pushing up; here's 4 for your watchlist The post Top Biotech Penny Stocks to Watch in June 2021? Here's 4 For Your List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Biotech Penny Stocks to Watch in June 2021? Here's 4 For Your List

New Gold

Looking for top penny stocks to buy under $2? Check these 3 out for some watchlist inspiration The post 3 Penny Stocks To Watch Under $2 Making Big Moves Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks To Watch Under $2 Making Big Moves Today

Advaxis Inc (NASDAQ: ADXS) announced updated data from its Phase 1/2 study evaluating ADXS-503 in combination with Merck & Co Inc's Keytruda (pembrolizumab) in patients with metastatic non-small-cell lung cancer (NSCLC). Data will be presented at the American Society of Clinical Oncology 2021 Annual Meeting.

Advaxis' ADXS-503 Shows Durable Benefit Beyond One Year in Lung Cancer Patients Progressing on Merck's Keytruda

The stock price of Advaxis, Inc. (NASDAQ: ADXS) increased by over 4% pre-market. This is why it happened.

Advaxis (ADXS) Stock: Over 4% Increase Pre-Market Explanation

Updated data show disease control rate of 44% with durable clinical benefit observed beyond one year in patients with disease progression on pembrolizumab

Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

Acasti Pharma

Agenus

Best biotech penny stocks to buy during the crypto crash? Check these 3 out The post Biotech Penny Stocks Pushing Up During The Crypto Crash, One Up 25% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Biotech Penny Stocks Pushing Up During The Crypto Crash, One Up 25%

The stock price of Advaxis, Inc. (NASDAQ: ADXS) increased by over 25% pre-market. This is why it happened.

Advaxis (ADXS) Stock: Over 25% Increase Pre-Market Explanation

Advaxis, Inc. is a small clinical-stage biotechnology company developing oncological therapeutics with their live attenuated Listeria monocytogenes antigen-delivery platform technology. Advaxis is currently developing three internal therapeutic programs ADXS-503 (Phase 1/2), ADXS-504 (Phase 1 expected in 2Q '21), and ADXS-PSA (Phase 1/2) for various oncology indications.

Advaxis: New Early Stage Pipeline Offers Significant, But Risky Upside

PRINCETON, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that will present data from Part B of the Phase 1 study of ADXS-503 in combination with pembrolizumab at the American Society of Clinical Oncology (ASCO) Annual Meeting being held virtually, on June 4-8, 2021.

Advaxis to Present at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

News for Advaxis Stock (ADXS)